Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Versatile Morphological Control of Cobalt Metal-Organic Frameworks with Enhanced Catalytic Activity by Simple Tuning of Precursor Conditions.

ACS applied materials & interfaces·2026
Same author

N-Succinylated Canonical vs. Dehydropeptides: Contrasting Self-Assembly Pathways and Hydrogel Properties.

Gels (Basel, Switzerland)·2026
Same author

Smart Magnetic Nanozyme for Multimodal Dynamic Regulation to Reverse Multidrug Resistance in Breast Cancer.

Molecular pharmaceutics·2026
Same author

Exploring the Potential Role of Manganese-Based Zeolitic Imidazolate Framework Nanoparticles in Cancer Therapy: <i>In vitro</i> Studies Using Lung Cancer Cells.

International journal of nanomedicine·2026
Same author

Unveiling Dipolar Interaction-Driven Magnetic Field Inhomogeneities in T<sub>2</sub> MRI Contrast Agents.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Biocompatible NaLn(WO<sub>4</sub>)<sub>2</sub> core-shell nanoplatelets for multimodal MRI contrast, NIR imaging, and high sensitivity infrared luminescent ratiometric thermometry.

Journal of materials chemistry. B·2025

Related Experiment Video

Updated: Nov 21, 2025

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.2K

Solid Lipid Particles for Lung Metastasis Treatment.

Lourdes Valdivia1, Lorena García-Hevia1, Manuel Bañobre-López2

  • 1Nanomedicine Group, University of Cantabria-IDIVAL, Herrera Oria s/n, 39011 Santander, Spain.

Pharmaceutics
|January 16, 2021
PubMed
Summary

Doxorubicin-loaded solid lipid particles (SLPs) effectively treat metastatic lung cancer by releasing chemotherapy over extended periods. This targeted approach reduces tumor growth and improves survival rates in mice.

Keywords:
cancerdoxorubicindrug deliverymelanomananomedicine

More Related Videos

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

18.3K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

7.5K

Related Experiment Videos

Last Updated: Nov 21, 2025

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.2K
Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

18.3K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

7.5K

Area of Science:

  • Nanotechnology in drug delivery
  • Oncology
  • Pharmacokinetics

Background:

  • Solid lipid particles (SLPs) offer sustained drug release, potentially improving therapeutic outcomes.
  • Doxorubicin is a key chemotherapy agent, but its use is limited by toxicity and biodistribution.
  • No prior studies have investigated doxorubicin-loaded SLPs for metastatic cancer treatment.

Purpose of the Study:

  • To characterize doxorubicin-loaded carnauba wax SLPs for treating lung metastatic malignant melanoma in vivo.
  • To evaluate the efficacy of these SLPs compared to free doxorubicin.

Main Methods:

  • Preparation and characterization of doxorubicin-loaded carnauba wax SLPs.
  • In vivo administration of SLPs and free doxorubicin in a mouse model of lung metastatic melanoma.
  • In vitro kinetic studies to determine drug release profiles.
  • Quantification of pulmonary metastatic foci.

Main Results:

  • Intravenously administered doxorubicin-loaded SLPs significantly reduced the number of pulmonary metastatic foci in mice compared to free doxorubicin.
  • In vitro studies revealed a biphasic drug release: an initial burst release (approx. 30% within 5 hours) followed by sustained release (>40 days).
  • Sustained release achieved constant in situ chemotherapy levels, inhibiting metastatic growth.

Conclusions:

  • Doxorubicin-loaded SLPs demonstrate significant potential for treating metastatic lung cancer.
  • The dual-phase release profile enhances local drug effectiveness and minimizes systemic toxicity.
  • This approach may improve overall survival and reduce side effects in cancer therapy.